CN105664109A - Pharmaceutical preparation for treating hypermenorrhea and use thereof - Google Patents

Pharmaceutical preparation for treating hypermenorrhea and use thereof Download PDF

Info

Publication number
CN105664109A
CN105664109A CN201610108753.3A CN201610108753A CN105664109A CN 105664109 A CN105664109 A CN 105664109A CN 201610108753 A CN201610108753 A CN 201610108753A CN 105664109 A CN105664109 A CN 105664109A
Authority
CN
China
Prior art keywords
parts
rhizoma
grams
pharmaceutical preparation
radix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201610108753.3A
Other languages
Chinese (zh)
Inventor
李晓峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201610108753.3A priority Critical patent/CN105664109A/en
Publication of CN105664109A publication Critical patent/CN105664109A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/234—Cnidium (snowparsley)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/286—Carthamus (distaff thistle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/344—Codonopsis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/486—Millettia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/489—Sophora, e.g. necklacepod or mamani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A61K36/575—Magnolia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/756—Phellodendron, e.g. corktree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/89—Cyperaceae (Sedge family)
    • A61K36/8905—Cyperus (flatsedge)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Abstract

The invention relates to a pharmaceutical preparation for treating hypermenorrhea. The pharmaceutical preparation contains rhizoma atractylodis, cortex phellodendri, atractylodes macrocephala, Sophora flavescens, rhizoma cyperi, rhizoma corydalis, eupatorium fortunei, glycyrrhiza uralensis, rhizoma chuanxiong, baked ginger, Semen Cuscutae, safflowers, spatholobus suberectus, antler gum, radix scutellariae, radix codonopsis pilosulae, cortex magnoliae officinalis, honey, cnidium monnieri and illicium verum. According to the pharmaceutical preparation for treating the hypermenorrhea and the use thereof, the medicines are in accordance with the theory of traditional Chinese medicine, so that the combination is more reasonable, the theory of traditional Chinese medicine is emphasized, and the Yin and Yang are balanced; the effects of improving blood circulation, invigorating Qi and nourishing blood, promoting blood circulation to dispel blood stasis, nourishing Yin and clearing heat and regulating Qi and alleviating pain are achieved through mutually matching all the medicines, the function of coagulating blood and arresting bleeding can be enhanced, and the drug effect and function can be more comprehensive so as to treats both symptoms and root causes.

Description

One is used for treating menorrheal pharmaceutical preparation and application thereof
Technical field
The invention belongs to medical treatment field, particularly relate to a kind of for treating menorrheal pharmaceutical preparation and application thereof.
Background technology
Deterioration along with living environment, in addition, operating pressure is big, easily causing women anxiety, depression, agitation, women is based on blood, and blood is with gas row, the menoxenia, the menstruation that cause due to the change of emotion increase phenomenon, wherein menorrheal definition is that in continuous several menstrual cycle, BTB amount is many, but menstruation interval time and bleeding time are all regular, without the unexpected increase of intermenstrual bleeding, postcoital bleeding or menses. Clinically with bleeding time and basal body temperature (BBT) curve control, ovulation type dysfunctional uterine bleeding will be had to be divided into menorrhagia and intermenstrual bleeding two class.
Menorrhagia, for common clinical, frequently-occurring disease, treats more thorny. Menstrual cycle is constant, and arranges and exceed normal through amount, or time lengthening of passing through, amount also thus increase, be called " menorrhagia ", menorrheal pathogeny, mainly caused by the deficiency of vital energy or heat in blood. It is because being natural endowment element Sheng, excess of YANG QI, arrogant then raw heat, and heat then blood oozing from the body openings or subcuta neous tissue is not kept and increased; Or the pungent dry product of surfeit, accumulation of heat in CHONG and REN meridians, the absurd row of forcing blood, cause and make blood volume add.
Drug therapy and operative treatment is had at present, wherein: first Drug therapy for menorrheal treatment. To requiring without contraception or being unwilling, with the patient of hormone therapy, to can be selected for anti-fibrinolytic medicine: such as tranexamic acid; Or anti-PG synthetic drug: flufenamic acid (flufenamic acid), mefenamic acid (mefenamic acid). Untoward reaction can have nauseating, dizzy, headache etc.; To the patient requiring contraception, can be selected for endometrial atrophy treatment: other: danazol is the derivant of 17a-etherone, it can suppress gonadotropin releasing hormone to secrete, suppress the generation of promoting sexual gland hormone cycle peak and ovarian sex hormone, can reduce blood loss, but it should be noted that erythra, liver damage, masculine side reaction. Gonadotropin releasing hormone synergist suppresses ovarian function effect certainly, because there being side reaction caused by low estrogen, and can only short application use. The effect of gossypol atrophy inner membrance is relatively strong, also can be done directly on ovary, need to add potassium chloride (slow release potassium), to prevent hypokalemia side reaction. The patient of fertility it is no longer required for suitable in menopause transition. Next is exactly operative treatment, Drug therapy is invalid, persistently do not heal, patient that older, atoke requires, can excision uterus.Adopt through cervix uteri endometrial resection (TCRE) art in recent years, namely through hysteroscope under the supervision of B ultrasonic acoustic inspection, the method adopting laser, microwave or coagulation, destroy functional layer and portion base layer, it is made to lose the respond to ovarian sex hormone, thus reducing MBL. This kind of operating time is short, and wound is little, recovers fast, is applicable to and should not or be reluctant also can cut out excision uterus and atoke claimer except muscular tumor under little mucosa simultaneously. Preoperative first with gonadotropin releasing hormone synergist atrophy inner membrance.
Summary of the invention
For the defect of prior art, the present invention be directed to the present situation for the treatment of at present, it is provided that one treats menorrheal pharmaceutical preparation, and has no side effect, effective.
Specifically, the concrete scheme of the present invention is achieved in that
First, inventor provides one according to drug matching experience and treats menorrheal pharmaceutical preparation, and the Chinese medicine ingredients contained in prescription is: Rhizoma Atractylodis, Cortex Phellodendri, the Rhizoma Atractylodis Macrocephalae, Radix Sophorae Flavescentis, Rhizoma Cyperi, Rhizoma Corydalis, Herba Eupatorii, Radix Glycyrrhizae, Rhizoma Chuanxiong, Rhizoma Zingiberis Preparatum, Semen Cuscutae, Flos Carthami, Caulis Spatholobi, Colla cornus cervi, Radix Scutellariae, Radix Codonopsis, Cortex Magnoliae Officinalis, Mel, Fructus Cnidii, Fructus Anisi Stellati.
Further, inventor provides one according to drug matching experience and treats menorrheal pharmaceutical preparation, each raw material dosage of prescription all has good curative effect in the weight portion scope of the present invention, described formula and weight portion be: Rhizoma Atractylodis 5-11 part, Cortex Phellodendri 6-14 part, Rhizoma Atractylodis Macrocephalae 6-17 part, Radix Sophorae Flavescentis 8-15 part, Rhizoma Cyperi 13-33 part, Rhizoma Corydalis 6-16 part, Herba Eupatorii 5-14 part, Radix Glycyrrhizae 9-12 part, Rhizoma Chuanxiong 10-15 part, Rhizoma Zingiberis Preparatum 5-11 part, Semen Cuscutae 6-18 part, Flos Carthami 10-22 part, Caulis Spatholobi 6-13 part, Colla cornus cervi 2-7 part, Radix Scutellariae 10-16 part, Radix Codonopsis 9-14 part, Cortex Magnoliae Officinalis 6-16 part, Mel 2-7 part, Fructus Anisi Stellati 3-12 part, Fructus Cnidii 1-5 part.
Further, the formula of above-mentioned weight portion is carried out preferably, reach superior technique effect, it is preferred that formula is: Rhizoma Atractylodis 8 parts, Cortex Phellodendri 10 parts, the Rhizoma Atractylodis Macrocephalae 12 parts, Radix Sophorae Flavescentis 12.5 parts, Rhizoma Cyperi 23 parts, Rhizoma Corydalis 11 parts, Herba Eupatorii 8 parts, 11 parts of Radix Glycyrrhizae, Rhizoma Chuanxiong 12 parts, Rhizoma Zingiberis Preparatum 8 parts, Semen Cuscutae 12 parts, 16 parts of Flos Carthami, Caulis Spatholobi 10 parts, Colla cornus cervi 4.5 parts, Radix Scutellariae 13 parts, Radix Codonopsis 12 parts, Cortex Magnoliae Officinalis 11 parts, Mel 4.5 parts, Fructus Anisi Stellati 7.5 parts, Fructus Cnidii 2.5 parts.
Or: Rhizoma Atractylodis 7 parts, Cortex Phellodendri 9 parts, the Rhizoma Atractylodis Macrocephalae 11 parts, Radix Sophorae Flavescentis 11.5 parts, Rhizoma Cyperi 22 parts, Rhizoma Corydalis 10 parts, Herba Eupatorii 8 parts, 10 parts of Radix Glycyrrhizae, Rhizoma Chuanxiong 12 parts, Rhizoma Zingiberis Preparatum 8 parts, Semen Cuscutae 11 parts, 16 parts of Flos Carthami, Caulis Spatholobi 10 parts, Colla cornus cervi 4.5 parts, Radix Scutellariae 13 parts, Radix Codonopsis 12 parts, Cortex Magnoliae Officinalis 11 parts, Mel 4.5 parts, Fructus Anisi Stellati 7.5 parts, Fructus Cnidii 3 parts.
In pharmaceutical preparation described above, the Chinese medicine used all uses its conventional medicinal part to be used as medicine, and the dosage of drug used is reasonable, and all medicines have good effect for treatment menorrhagia after share.
The function of each taste Chinese crude drug used in the pharmaceutical preparation of the treatment of the present invention is as follows:
Fructus Cnidii: bitter in the mouth, warm in nature.
Gui Jing: return kidney channel.
Function cures mainly: warming the kidney to invigorate YANG, and dampness is dispeled the wind, parasite killing. Cold womb, cold-damp leukorrhagia, arthralgia chiefly caused by damp pathogen lumbago; External treatment vulval eczema, married woman's pudendal pruritus, trichomonal vaginitis.
Radix Scutellariae: bitter in the mouth, cold in nature.
Gui Jing: return lung, gallbladder, spleen, large intestine, small intestine meridian.
Function cures mainly: heat clearing and damp drying, eliminating fire and detoxication, hemostasis, antiabortive.For hygropyrexia, fever disease in summer vomiting and nausea uncomfortable in chest, damp and hot feeling of fullness, dysentery, jaundice, cough due to lung-heat, high hot excessive thirst, heat in blood tells nosebleed, carbuncle sore tumefacting virus, frequent fetal movement.
Fructus Anisi Stellati: acrid in the mouth, warm in nature.
Gui Jing: return liver,kidney,spleen, stomach warp.
Function cures mainly: warming YANG to expel cold, regulating QI to relieve pain. Suffer from abdominal pain for colic of cold type, kidney
Virtual waist pain, gastrofrigid vomiting, coldness and pain in the epigastrium.
Cortex Magnoliae Officinalis: bitter in the mouth, pungent, temperature.
Gui Jing: return spleen, stomach, lung, large intestine channel.
Function cures mainly: dampness expectorant, and the therapeutic method to keep the adverse QI flowing downwards is except full. For humidity hysteresis damaging the spleen and stomach, gastral cavity painful abdominal mass is vomited and diarrhoea, and stagnation of QI due to dyspepsia, abdominal distention constipation, phlegm retention is breathed with cough.
Radix Codonopsis: sweet in the mouth, property is put down.
Gui Jing: return spleen, lung meridian.
Function cures mainly: invigorating the spleen and replenishing QI, spleen invigorating lung benefiting. For deficiency of the spleen and lung, cardiopalmus of breathing hard, anorexia and loose stool, dyspnea due to deficiency is coughed, and interior-heat is quenched one's thirst.
Mel: nature and flavor are sweet is flat.
Gui Jing: return lung, spleen, large intestine channel.
Function cures mainly: invigorating middle warmer, moisturizes, pain relieving, removing toxic substances. For gastral cavity abdomen void pain, dryness of the lung dry cough, dryness of the intestine constipation; External treatment skin infection is not held back, burn due to hot liquid or fire.
Semen Cuscutae: sweet in the mouth, warm in nature.
Gui Jing: return liver,kidney,spleen warp.
Function cures mainly: nourishing the liver and kidney, controlling nocturnal emission with astringent drugs reducing urination, antiabortive, improving eyesight, antidiarrheal, and for impotence and seminal emission, dripping urination, enuresis frequent micturition, soreness of the waist and knees, blurred vision tinnitus, vaginal bleeding due to deficiency of the kidney during pregnancy, frequent fetal movement, spleen is suffered from a deficiency of the kidney and rushed down.
Flos Carthami: acrid in the mouth, warm in nature.
Gui Jing: GUIXIN, Liver Channel.
Function cures mainly: promoting blood circulation to restore menstrual flow, eliminating stasis to stop pain. For amenorrhea, dysmenorrhea, lochia, lump in the abdomen mass in the abdomen, injury from falling down, skin infection swells and ache.
Caulis Spatholobi: bitter in the mouth, sweet, warm in nature.
Gui Jing: return liver, kidney channel.
Function cures mainly: enrich blood, and invigorates blood circulation, dredging collateral, blood deficiency and yellow complexion, paralysis and numbness, rheumatic arthralgia.
Colla cornus cervi: sweet in the mouth, salty, warm in nature, return kidney, Liver Channel.
Function cures mainly: temperature compensation Liver and kidney, and benefit intensive culture blood, cold for waist knee joint acid, asthenia weakness and emaciation, metrostaxis, hematuria of having blood in stool, carbuncle of yin nature swells and ache.
Rhizoma Zingiberis Preparatum: acrid in the mouth, hot in nature, returns spleen, stomach, kidney, the heart, lung meridian.
Function cures mainly warming spleen and stomach for dispelling cold, warming the meridian for stopping bleeding. For Deficiency and coldness of spleen and stomach, stomachache is vomited and diarrhoea, and tells nosebleed metrorrhagia, and yang deficiency is lost blood.
Rhizoma Chuanxiong: acrid in the mouth, warm in nature, return liver, gallbladder, pericardium channel.
Function cures mainly: blood-activating and qi-promoting, wind-expelling pain-stopping. For menoxenia, amenorrhea dysmenorrhea, lump in the abdomen is suffered from abdominal pain, breast side of body twinge, tumbling and swelling, headache, rheumatic arthralgia.
Radix Sophorae Flavescentis: bitter in the mouth, cold in nature.
Gui Jing: GUIXIN, liver, stomach, large intestine, bladder warp.
Function cures mainly: heat clearing and damp drying, parasite killing diuresis, has blood in stool for hematodiarrhoea, jaundice urine retention, leucorrhea with red and white discharge, swelling of the vulva pudendal pruritus, external treatment trichomonal vaginitis.
Rhizoma Cyperi: bitter in the mouth, property is put down.
Gui Jing: return liver, spleen, tri-jiao channel.
Function cures mainly: promoting QI circulation for relieving depression, menstruction regulating and pain relieving. For stagnation of QI due to depression of the liver, breast, the side of body, abdominal distention, dyspepsia, breast gastral cavity painful abdominal mass is vexed, and colic of cold type is suffered from abdominal pain, distending pain of the breast, menoxenia, amenorrhea dysmenorrhea.
Cortex Phellodendri: bitter in the mouth, cold in nature.
Gui Jing: return kidney, bladder warp.
Function cures mainly: heat clearing and damp drying, and pathogenic fire purging is except steaming, detoxification sore treatment.
The Rhizoma Atractylodis Macrocephalae: bitter in the mouth, warm in nature.
Gui Jing: return spleen, stomach warp.
Function cures mainly: invigorating the spleen and benefiting QI, dampness diuretic, and hidroschesis is antiabortive. For insufficiency of the spleen lack of appetite, abdominal distention is had loose bowels, phlegm retention vertigo and palpitation, edema, spontaneous perspiration, frequent fetal movement
Rhizoma Corydalis: acrid in the mouth, hardship, warm in nature.
Function cures mainly: promoting blood circulation to remove blood stasis, the function of promoting the circulation of QI pain relieving.
The various clinical medicine dosage forms of pharmaceutical preparation of the present invention can be granule, capsule, tablet, injection, tincture, suppository, pill, syrup, mixture, powder, lotion, membrane, drop pill etc.
Pharmaceutical preparation of the present invention is compared with prior art, compared with prior art, compatibility is more reasonable, focuses on theory of Chinese medical science for the preparation of medicine of the present invention, negative and positive are balanced, all medicines are collocated with each other and reach to improve blood circulation, benefiting QI and nourishing blood, blood circulation promoting and blood stasis dispelling, nourishing YIN and clearing away heat, the effect of regulating QI to relieve pain, it can strengthen blood coagulation hemostatic function, makes drug effect and function more fully treating both the principal and secondary aspects of a disease.
Specific embodiment
It is obvious to a person skilled in the art that the details of the embodiment of the present invention, and when without departing substantially from the spirit of the present invention or basic feature, it is possible to realize the present invention in other specific forms. Embodiment all should be regarded as exemplary, and be nonrestrictive, it is intended that all changes in the implication of the equivalency dropping on claim and scope are included in the present invention.
Embodiment 1: a kind of treat the pharmaceutical preparation that menstruation increases, each composition according to weight ratio is:
Rhizoma Atractylodis 5 grams, Cortex Phellodendri 6 grams, the Rhizoma Atractylodis Macrocephalae 6 grams, Radix Sophorae Flavescentis 8 grams, Rhizoma Cyperi 13 grams, Rhizoma Corydalis 6 grams, Herba Eupatorii 5 grams, 9 grams of Radix Glycyrrhizae, Rhizoma Chuanxiong 10 grams, Rhizoma Zingiberis Preparatum 5 grams, Semen Cuscutae 6 grams, 10 grams of Flos Carthami, Caulis Spatholobi 6 grams, Colla cornus cervi 2 grams, Radix Scutellariae 10 grams, Radix Codonopsis 9 grams, Cortex Magnoliae Officinalis 6 grams, Mel 2 grams, Fructus Anisi Stellati 3 grams, Fructus Cnidii 1 gram.
Above Chinese drug preparation is become capsule, and preparation method is as follows:
(1) by above-mentioned weight ratio weighting raw materials boiling twice, adding 8 times amount water every time, decoct 1 hour for the 1st time, second time decocts 40 minutes, and merging filtrate, after filtration, is dried to fine powder; (2) fine powder in step (1) is added anhydrous grape Icing Sugar mix homogeneously; (3) above-mentioned mixed-powder is put into capsule filling machine and carry out filling, namely obtain the capsule of every 250mg.
Embodiment 2: a kind of treat the pharmaceutical preparation that menstruation increases, each composition according to weight ratio is:
Rhizoma Atractylodis 11 grams, Cortex Phellodendri 14 grams, the Rhizoma Atractylodis Macrocephalae 17 grams, Radix Sophorae Flavescentis 15 grams, Rhizoma Cyperi 33 grams, Rhizoma Corydalis 16 grams, Herba Eupatorii 14 grams, 12 grams of Radix Glycyrrhizae, Rhizoma Chuanxiong 15 grams, Rhizoma Zingiberis Preparatum 11 grams, Semen Cuscutae 18 grams, 22 grams of Flos Carthami, Caulis Spatholobi 13 grams, Colla cornus cervi 7 grams, Radix Scutellariae 16 grams, Radix Codonopsis 14 grams, Cortex Magnoliae Officinalis 16 grams, Mel 7 grams, Fructus Anisi Stellati 12 grams, Fructus Cnidii 5 grams.
Preparation method is with embodiment 1.
Embodiment 3: a kind of treat the pharmaceutical preparation that menstruation increases, each composition according to weight ratio is:
Rhizoma Atractylodis 8 grams, Cortex Phellodendri 10 grams, the Rhizoma Atractylodis Macrocephalae 12 grams, Radix Sophorae Flavescentis 12.5 grams, Rhizoma Cyperi 23 grams, Rhizoma Corydalis 11 grams, Herba Eupatorii 8 grams, 11 grams of Radix Glycyrrhizae, Rhizoma Chuanxiong 12 grams, Rhizoma Zingiberis Preparatum 8 grams, Semen Cuscutae 12 grams, 16 grams of Flos Carthami, Caulis Spatholobi 10 grams, Colla cornus cervi 4.5 grams, Radix Scutellariae 13 grams, Radix Codonopsis 12 grams, Cortex Magnoliae Officinalis 11 grams, Mel 4.5 grams, Fructus Anisi Stellati 7.5 grams, Fructus Cnidii 2.5 grams.
Preparation method is with embodiment 1.
Embodiment 4: a kind of treat the pharmaceutical preparation that menstruation increases, each composition according to weight ratio is:
Rhizoma Atractylodis 7 grams, Cortex Phellodendri 9 grams, the Rhizoma Atractylodis Macrocephalae 11 grams, Radix Sophorae Flavescentis 11.5 grams, Rhizoma Cyperi 22 grams, Rhizoma Corydalis 10 grams, Herba Eupatorii 8 grams, 10 grams of Radix Glycyrrhizae, Rhizoma Chuanxiong 12 grams, Rhizoma Zingiberis Preparatum 8 grams, Semen Cuscutae 11 grams, 16 grams of Flos Carthami, Caulis Spatholobi 10 grams, Colla cornus cervi 4.5 grams, Radix Scutellariae 13 grams, Radix Codonopsis 12 grams, Cortex Magnoliae Officinalis 11 grams, Mel 4.5 grams, Fructus Anisi Stellati 7.5 grams, Fructus Cnidii 3 grams.
Preparation method is with embodiment 1.
Embodiment 5: a kind of treat the pharmaceutical preparation that menstruation increases, each composition according to weight ratio is:
Rhizoma Atractylodis 8 grams, Cortex Phellodendri 10 grams, the Rhizoma Atractylodis Macrocephalae 12 grams, Radix Sophorae Flavescentis 12.5 grams, Rhizoma Cyperi 23 grams, Rhizoma Corydalis 11 grams, Herba Eupatorii 8 grams, 11 grams of Radix Glycyrrhizae, Rhizoma Chuanxiong 12 grams, Rhizoma Zingiberis Preparatum 8 grams, Semen Cuscutae 12 grams, 16 grams of Flos Carthami, Caulis Spatholobi 10 grams, Colla cornus cervi 4.5 grams, Radix Scutellariae 13 grams, Radix Codonopsis 12 grams, Cortex Magnoliae Officinalis 11 grams, Mel 4.5 grams, Fructus Anisi Stellati 7.5 grams, Fructus Cnidii 2.5 grams.
Above Chinese medicine preparation is prepared into pill, and preparation method is as follows:
(1) by above-mentioned weight ratio weighting raw materials boiling twice, adding 8 times amount water, first time decocts 1 hour, and second time decocts 40 minutes, merging filtrate every time, after filtration, is dried to fine powder, crosses 100 mesh sieves; (2) by celphere (granule with sugar with the 30-40 order made by starch mixing), it is placed in coating granulator; (3) with pregelatinized Starch ethanol for wet adhesive, the granule-starch solids dispersion of 100 orders is added with certain speed so that it is be uniformly adhered in celphere surface; (4) dry, screen 20-40 mesh sieve piller, to obtain final product.
Embodiment 6: a kind of treat the pharmaceutical preparation that menstruation increases, each composition according to weight ratio is:
Rhizoma Atractylodis 7 grams, Cortex Phellodendri 9 grams, the Rhizoma Atractylodis Macrocephalae 11 grams, Radix Sophorae Flavescentis 11.5 grams, Rhizoma Cyperi 22 grams, Rhizoma Corydalis 10 grams, Herba Eupatorii 8 grams, 10 grams of Radix Glycyrrhizae, Rhizoma Chuanxiong 12 grams, Rhizoma Zingiberis Preparatum 8 grams, Semen Cuscutae 11 grams, 16 grams of Flos Carthami, Caulis Spatholobi 10 grams, Colla cornus cervi 4.5 grams, Radix Scutellariae 13 grams, Radix Codonopsis 12 grams, Cortex Magnoliae Officinalis 11 grams, Mel 4.5 grams, Fructus Anisi Stellati 7.5 grams, Fructus Cnidii 3 grams.
Preparation method is with embodiment 5.
Embodiment 7: a kind of treat the pharmaceutical preparation that menstruation increases, each composition according to weight ratio is:
Rhizoma Atractylodis 8 grams, Cortex Phellodendri 10 grams, the Rhizoma Atractylodis Macrocephalae 12 grams, Radix Sophorae Flavescentis 12.5 grams, Rhizoma Cyperi 23 grams, Rhizoma Corydalis 11 grams, Herba Eupatorii 8 grams, 11 grams of Radix Glycyrrhizae, Rhizoma Chuanxiong 12 grams, Rhizoma Zingiberis Preparatum 8 grams, Semen Cuscutae 12 grams, 16 grams of Flos Carthami, Caulis Spatholobi 10 grams, Colla cornus cervi 4.5 grams, Radix Scutellariae 13 grams, Radix Codonopsis 12 grams, Cortex Magnoliae Officinalis 11 grams, Mel 4.5 grams, Fructus Anisi Stellati 7.5 grams, Fructus Cnidii 2.5 grams.
Above Chinese medicine preparation is prepared into tablet, and preparation method is as follows:
The Chinese medicine taking above amount decocts, decoct rear medicinal liquid to concentrate, be concentrated into finite concentration (proportion is about 1:1), after cold, add 1.1 times of ethanol put, fully mixing, place overnight so that it is precipitation, take its supernatant (filtering if desired) next day, precipitate is cleaned with a small amount of 52% ethanol, washing liquid merges with filtrate, after decompression recycling ethanol, to be concentrated to finite concentration time add a certain amount of water. Mixing stands certain time, makes precipitation complete, rate mistake, filtrate low-temperature evaporation to paste, adds suitable dextrin, pregelatinized Starch, magnesium stearate, adjuvant, after mixing in powdered extract powder, add and be pressed into progressively whole to satisfactory granularity, carry out tabletting, obtain tablet.
Embodiment 8: a kind of treat the pharmaceutical preparation that menstruation increases, each composition according to weight ratio is:
Rhizoma Atractylodis 8 grams, Cortex Phellodendri 10 grams, the Rhizoma Atractylodis Macrocephalae 12 grams, Radix Sophorae Flavescentis 12.5 grams, Rhizoma Cyperi 23 grams, Rhizoma Corydalis 11 grams, Herba Eupatorii 8 grams, 11 grams of Radix Glycyrrhizae, Rhizoma Chuanxiong 12 grams, Rhizoma Zingiberis Preparatum 8 grams, Semen Cuscutae 12 grams, 16 grams of Flos Carthami, Caulis Spatholobi 10 grams, Colla cornus cervi 4.5 grams, Radix Scutellariae 13 grams, Radix Codonopsis 12 grams, Cortex Magnoliae Officinalis 11 grams, Mel 4.5 grams, Fructus Anisi Stellati 7.5 grams, Fructus Cnidii 2.5 grams.
Above Chinese medicine preparation is prepared into granule, and preparation method is as follows:
The Chinese medicine more than measured conventionally decocts, decoct rear medicinal liquid to carry out being concentrated into the concentration that proportion is 1:1.2, 1.5 times of ethanol put are added after cold, fully mixing, place overnight, make it precipitate, take its supernatant next day, precipitate is cleaned with a small amount of 50% ethanol, washing liquid merges with filtrate, after decompression recycling ethanol, to be concentrated to finite concentration time shift storing cold place standing certain time, make precipitation complete, rate mistake, filtrate low-temperature evaporation is to paste, powdered extract powder adds suitable starch and calcium phosphate adjuvant, after mixing, cross 200 mesh sieves, obtain granule.
Embodiment 9: the impact on the mice bleeding time
Take female underage rat 50, often group 10, be divided into 5 groups, namely Normal group group (isometric(al)), positive controls (SANQI ZHIXUE PIAN 0.5g kg-1), three dosage groups (low dosage 1g kg of pharmaceutical composition of the present invention-1, middle dosage group 2g kg-1And heavy dose group 5g kg-1). Continuous 7 days, administering mode is table 1 such as:
It is as follows that table 1 respectively organizes administering mode, quantity, administration kind and dosage
Group Quantity Administering mode Administration kind Dosage (g/kg)
Normal group 10 Gavage Normal saline 2
Positive controls 10 Gavage SANQI ZHIXUE PIAN 0.5
Capsule high dose group 10 Gavage The embodiment of the present invention 3 5
Dosage group in capsule 10 Gavage The embodiment of the present invention 3 2
Capsule low dose group 10 Gavage The embodiment of the present invention 3 1
Being administered continuous 7d as stated above, 45min after last is administered, with the hemorrhage bleeding time cutting tail method mensuration mice. Result shows, medicine of the present invention can substantially shorten the bleeding time of mice, in Table 1.
The bleeding time situation that mice respectively organized by table 2 is as follows
Note:
Compared with adjuvant group$P < 0.05,$$P < 0.01
Compared with positive controls groupP < 0.05,P < 0.01
As can be seen from Table 2, the bleeding time that capsule is respectively organized is compared with Normal group, there is significant difference (P < 0.01 or P < 0.05), the bleeding time that wherein capsule is high is compared with positive controls, there is significant difference (P < 0.05), illustrate that the therapeutic effect of pharmaceutical preparation of the present invention is better, be suitable for carrying out popularization and application further.
9.2, the impact on clotting time of mice
Take female underage rat 50, often group 10, be divided into 5 groups, namely Normal group group (isometric(al)), positive controls (SANQI ZHIXUE PIAN 0.5g kg-1), three dosage groups (low dosage 1g kg of pharmaceutical composition of the present invention-1, middle dosage group 2g kg-1And heavy dose group 5g kg-1). Continuous 7 days, administering mode is table 1 such as:
It is as follows that table 3 respectively organizes administering mode, quantity, administration kind and dosage
Group Quantity Administering mode Administration kind Dosage (g/kg)
Normal group 10 Gavage Normal saline 2
Positive controls 10 Gavage SANQI ZHIXUE PIAN 0.5
Capsule high dose group 10 Gavage The embodiment of the present invention 3 5
Dosage group in capsule 10 Gavage The embodiment of the present invention 3 2
Capsule low dose group 10 Gavage The embodiment of the present invention 3 1
It is administered by table 3,45min after last is administered, surveys the clotting time of mice by capillary glass-tube method, namely insert mice ophthalmic corner of the eyes ball rear vein beard with the capillary glass-tube that internal diameter is 1mm and take blood, take blood to 5cm, fracture glass-tube once every 30s, check for solidifying silk to occur, and record clotting time. Result shows, medicine of the present invention can substantially shorten the clotting time of mice, in Table 4.
The clotting time situation that mice respectively organized by table 4 is as follows
Note:
Compared with adjuvant group$P < 0.05,$$P < 0.01
Compared with positive controls groupP < 0.05,P < 0.01
As can be seen from Table 4, the bleeding time that capsule is respectively organized is compared with Normal group, there is significant difference (P < 0.01 or P < 0.05), wherein capsule high, in bleeding time compared with positive controls, there is significant difference (P < 0.05), illustrate that the therapeutic effect of pharmaceutical preparation of the present invention is better, be suitable for carrying out popularization and application further.
Embodiment 10: animal model test and experiment in vitro
By embodiment 1,2, the capsule of embodiment 3 that uses in the pharmaceutical preparation alternate embodiment 9 prepared of 4-8, repeat embodiment 9, found that embodiment 1,2, the therapeutic effect of pharmaceutical preparation prepared of 4-8 identical with the capsule of embodiment 3, it may be determined that the therapeutic effect of the present invention.
Embodiment 11: clinical trial
11.1, ordinary circumstance
2013.10-2015.12 year 413 patients, get rid of organic disease 13 example, 400 example patients therein are selected to test, age 18-42 year, 33.2 years old mean age, 400 example patients are randomly divided into two groups, difference that between two groups, in mean age, average course of disease, the state of an illness, there are no significant (p > 0.05), there is comparability.
11.2, packet and administration
Treatment group: 200 examples: 18～42 years old age, 33.2 years old mean age; The course of disease is the shortest 6 months, the longest 15 years, average course of disease 5.1 years. The capsule of the embodiment of the present invention 3, oral, one time 2,2 times on the one, warm water delivery service, 3 months is 1 course for the treatment of, treats 2 courses for the treatment of.
Observation group: 200 examples: 18～42 years old age, 33.2 years old mean age; The course of disease is the shortest 6 months, the longest 15 years, average course of disease 5.3 years. Adopting WUJI BAIFENG WAN, oral, one time 6 grams (1 ball), 2 times on the one, warm water delivery service, 3 months is 1 course for the treatment of, treats 2 courses for the treatment of.
11.3, diagnostic criteria
Lab testing:
The detection of blood routine examination hormonal readiness, coagulation function, hematoblastic adhesive function are surveyed with aggregation capability inspection and are made inner membrance or blood progesterone mensuration when BT selects
Other auxiliary examination:
Hysteroscope, peritoneoscope Type B are ultrasonic, uterine arteriography inspection.
Do not meet normal value, check and once all meet menorrhagia person, be the test case of the present invention.
11.4, criterion of therapeutical effect
Cure: menstrual blood loss, menstrual cycle recover normal, and after drug withdrawal, 5 menstrual cycle are without repeatedly.
Effective: menstrual blood loss, menstrual cycle are normal, have clear improvement, after drug withdrawal, 5 menstrual cycle are without repeatedly.
Invalid: menstrual blood loss, menstrual cycle are not improved.
11.5, therapeutic outcome
Through the treatment of 6 months, the therapeutic effect for the treatment of group and observation group such as table 3.
The therapeutic effect of table 5 treatment group and observation group
Group Cure Effective Invalid Effective percentage (%)
Treatment group 145 53 2 99.5
Observation group 88 79 43 78.5
From table 3 it can be seen that treatment group: 145 examples of fully recovering, aobvious 53 examples, invalid 2 examples, effective percentage (recovery from illness+effective) 99.5%; Observation group fully recovers 88 examples, effective 79 examples, invalid 43 examples, effective percentage (recovery from illness+effective) 78.5%. The total effective rate for the treatment of group and observation group's group passes through χ2Inspection, has diversity notable, p≤0.01. The capsule effect of regulating menstruation of the present invention is notable, and effective percentage is high.
11.6, model case
Case 1: China certain, female, 25 years old, Lianyungang of Jiangsu people, pharmaceutical factory workman, patient's private prosecution working does not have regularity, often works overtime, and menstruation is abnormal, and amount is also abnormal, menstrual cycle before not giving birth to is 30 days, and menstrual cycle 15-20 days is not etc. afterwards, and fidgety with ambition, empty and bearing-down sensation of the lower abdomen symptom. Taking the capsule of the embodiment of the present invention 3, secondary month menstrual phase cycle changed 22 days into. Menstrual blood volume reduces, and continues to take 2 months, recovers normal, and 1 year Effect of follow-up visit by telephone does not recur.
Case 2: strict so-and-so, female, 19 years old, people from Dali, these administrative affairs of village agriculture, just abnormal after patient menstrual is first, and amount is extremely many and irregular, before coming hospital, menorrhagia injection last time 800cc blood, ate plurality of Chinese, effect is poor, introducing my institute through friend to check, take the capsule of the embodiment of the present invention 4, within secondary month, menstrual blood volume is shown in few, menstrual cycle is 26 days, continues to take 2 months, and menstrual blood volume recovers normal, menstrual cycle is 30 days, 1 year Effect of follow-up visit by telephone, does not recur.

Claims (7)

1. one kind is used for treating menorrheal pharmaceutical preparation, it is characterized in that, described pharmaceutical preparation includes following Chinese crude drug: Rhizoma Atractylodis, Cortex Phellodendri, the Rhizoma Atractylodis Macrocephalae, Radix Sophorae Flavescentis, Rhizoma Cyperi, Rhizoma Corydalis, Herba Eupatorii, Radix Glycyrrhizae, Rhizoma Chuanxiong, Rhizoma Zingiberis Preparatum, Semen Cuscutae, Flos Carthami, Caulis Spatholobi, Colla cornus cervi, Radix Scutellariae, Radix Codonopsis, Cortex Magnoliae Officinalis, Mel, Fructus Cnidii, Fructus Anisi Stellati.
2. pharmaceutical preparation according to claim 1, it is characterized in that, described pharmaceutical preparation includes following weight portion Chinese crude drug: Rhizoma Atractylodis 5-11 part, Cortex Phellodendri 6-14 part, Rhizoma Atractylodis Macrocephalae 6-17 part, Radix Sophorae Flavescentis 8-15 part, Rhizoma Cyperi 13-33 part, Rhizoma Corydalis 6-16 part, Herba Eupatorii 5-14 part, Radix Glycyrrhizae 9-12 part, Rhizoma Chuanxiong 10-15 part, Rhizoma Zingiberis Preparatum 5-11 part, Semen Cuscutae 6-18 part, Flos Carthami 10-22 part, Caulis Spatholobi 6-13 part, Colla cornus cervi 2-7 part, Radix Scutellariae 10-16 part, Radix Codonopsis 9-14 part, Cortex Magnoliae Officinalis 6-16 part, Mel 2-7 part, Fructus Anisi Stellati 3-12 part, Fructus Cnidii 1-5 part.
3. pharmaceutical preparation according to claim 1, it is characterized in that, described pharmaceutical preparation includes following weight portion Chinese crude drug: Rhizoma Atractylodis 8 parts, Cortex Phellodendri 10 parts, the Rhizoma Atractylodis Macrocephalae 12 parts, Radix Sophorae Flavescentis 12.5 parts, Rhizoma Cyperi 23 parts, Rhizoma Corydalis 11 parts, Herba Eupatorii 8 parts, 11 parts of Radix Glycyrrhizae, Rhizoma Chuanxiong 12 parts, Rhizoma Zingiberis Preparatum 8 parts, Semen Cuscutae 12 parts, 16 parts of Flos Carthami, Caulis Spatholobi 10 parts, Colla cornus cervi 4.5 parts, Radix Scutellariae 13 parts, Radix Codonopsis 12 parts, Cortex Magnoliae Officinalis 11 parts, Mel 4.5 parts, Fructus Anisi Stellati 7.5 parts, Fructus Cnidii 2.5 parts.
4. pharmaceutical preparation according to claim 1, it is characterized in that, described pharmaceutical preparation includes following weight portion Chinese crude drug: Rhizoma Atractylodis 7 parts, Cortex Phellodendri 9 parts, the Rhizoma Atractylodis Macrocephalae 11 parts, Radix Sophorae Flavescentis 11.5 parts, Rhizoma Cyperi 22 parts, Rhizoma Corydalis 10 parts, Herba Eupatorii 8 parts, 10 parts of Radix Glycyrrhizae, Rhizoma Chuanxiong 12 parts, Rhizoma Zingiberis Preparatum 8 parts, Semen Cuscutae 11 parts, 16 parts of Flos Carthami, Caulis Spatholobi 10 parts, Colla cornus cervi 4.5 parts, Radix Scutellariae 13 parts, Radix Codonopsis 12 parts, Cortex Magnoliae Officinalis 11 parts, Mel 4.5 parts, Fructus Anisi Stellati 7.5 parts, Fructus Cnidii 3 parts.
5. pharmaceutical preparation according to claim 1, it is characterised in that: described pharmaceutical dosage form one in granule, capsule, tablet, injection, tincture, suppository, pill, syrup, mixture, powder, lotion, membrane, drop pill.
6. the preparation method of pharmaceutical preparation according to claim 1, it is characterised in that: described pharmaceutical dosage form is selected from the one of capsule, tablet.
7. pharmaceutical preparation according to claim 1, it is characterised in that: described pharmaceutical preparation purposes in preparation treatment menorrhagia medicine.
CN201610108753.3A 2016-02-26 2016-02-26 Pharmaceutical preparation for treating hypermenorrhea and use thereof Withdrawn CN105664109A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610108753.3A CN105664109A (en) 2016-02-26 2016-02-26 Pharmaceutical preparation for treating hypermenorrhea and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610108753.3A CN105664109A (en) 2016-02-26 2016-02-26 Pharmaceutical preparation for treating hypermenorrhea and use thereof

Publications (1)

Publication Number Publication Date
CN105664109A true CN105664109A (en) 2016-06-15

Family

ID=56306166

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610108753.3A Withdrawn CN105664109A (en) 2016-02-26 2016-02-26 Pharmaceutical preparation for treating hypermenorrhea and use thereof

Country Status (1)

Country Link
CN (1) CN105664109A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101129916A (en) * 2007-08-21 2008-02-27 王军 Chinese angelica rhizoma corydalis honey bolus
CN104013762A (en) * 2014-06-26 2014-09-03 夏征梅 Traditional Chinese medicine composition for treating menorrhagia
CN104940509A (en) * 2015-07-27 2015-09-30 青岛蓝盛洋医药生物科技有限责任公司 Application of medicine composition in preparing medicine for treating gynecology hemorrhage syndrome

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101129916A (en) * 2007-08-21 2008-02-27 王军 Chinese angelica rhizoma corydalis honey bolus
CN104013762A (en) * 2014-06-26 2014-09-03 夏征梅 Traditional Chinese medicine composition for treating menorrhagia
CN104940509A (en) * 2015-07-27 2015-09-30 青岛蓝盛洋医药生物科技有限责任公司 Application of medicine composition in preparing medicine for treating gynecology hemorrhage syndrome

Similar Documents

Publication Publication Date Title
CN101926961B (en) Oral Chinese medicinal composition for treating pelvic inflammatory disease
CN102151325A (en) Traditional Chinese medicine for treating breast diseases
CN1895434B (en) Medicine for treating hysteromyoma
CN104922633A (en) Traditional Chinese medicine composition for treating arthralgia as well as preparation method and application method thereof
CN103071105B (en) External traditional Chinese medicinal preparation for treating threatened abortion and preparation method thereof
CN104524071A (en) Pharmaceutical composition for treating primary renal disease and application thereof
CN101569738A (en) Plaster for treating mastitis, hyperplasia of mammary glands, breast lumps, join thydrops, traumatic injury, preparation method and application thereof
CN103272189B (en) Medicine for curing gallstones
CN100431569C (en) Chinese medicine prepn for treating dysmenorrhea
CN102343019B (en) Chinese medicinal composition for treating amenorrhea and preparation method of preparation thereof
CN100371016C (en) Chinese traditional medicine preparation for curing mastopathy in installments
CN100571747C (en) A kind of Chinese medicine decoction for the treatment of dysmenorrhea
CN105664109A (en) Pharmaceutical preparation for treating hypermenorrhea and use thereof
CN102895564A (en) Chinese medicine for treating tubal nowhere and preparation method thereof
CN104547700B (en) A kind of Chinese medicine composition for the treatment of preceeded menorrhea
CN104257813B (en) A kind of Chinese medicine composition of QI and blood regulating and preparation method thereof
CN101869629B (en) Traditional Chinese medicine for treating renal calculus
CN105833209A (en) Traditional Chinese medicine composition for treating endometriosis uterina
CN105311396A (en) Traditional Chinese medicine preparation for treating hypomenorrhea caused by thin endometrium
CN105395768A (en) Pharmaceutical composition for treating qi-blood deficiency type hypomenorrhea
CN104491719A (en) Traditional Chinese medicine composition for treating cervical cancers
CN105920457B (en) Traditional Chinese medicine composition for treating tubal nowhere
CN104208546A (en) Asthma medicine
CN104547412A (en) Traditional Chinese medicine preparation for treating hysteromyoma
CN104257965A (en) Traditional Chinese medicine for treating knee joint hyperostosis via oral and external administration and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20160615

WW01 Invention patent application withdrawn after publication